Skip to content
HowShorted

Nektar Therapeutics short interest in 2020

In 2020, Nektar Therapeutics's disclosed short interest ran from 16.82% of shares outstanding on 15 Jan 2020 to 13.49% on 31 Dec 2020, a change of -3.33 percentage points. The year's high was 16.82% on 15 Jan 2020 and its low 13.49% on 31 Dec 2020, averaging 15.02% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 45.05 days on 31 Jul 2020. Full history: Nektar Therapeutics.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Nektar Therapeutics in 2020

2020 in figures

Start of year
16.82% (15 Jan 2020)
End of year
13.49% (31 Dec 2020)
Change
-3.33 pp
High
16.82% (15 Jan 2020)
Low
13.49% (31 Dec 2020)
Average
15.02%
Highest days to cover
45.05 (31 Jul 2020)
SEC filings marked
9

Every report in 2020

Nektar Therapeutics short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202016.82%8.57results (8-K)
31 Jan 202016.31%16.02
14 Feb 202015.75%20.10
28 Feb 202015.39%15.66results (8-K), 10-K filed
13 Mar 202015.59%17.26
31 Mar 202015.71%16.89
15 Apr 202016.11%26.09
30 Apr 202015.97%26.96
15 May 202015.58%22.35results (8-K), 10-Q filed
29 May 202015.06%28.92
15 Jun 202015.56%22.46
30 Jun 202015.37%26.37
15 Jul 202015.02%33.14
31 Jul 202014.96%45.05
14 Aug 202014.77%35.14results (8-K), 10-Q filed
31 Aug 202014.67%33.74
15 Sep 202014.42%28.16
30 Sep 202014.24%21.31
15 Oct 202014.47%30.45
30 Oct 202014.07%24.24
13 Nov 202013.77%22.02results (8-K), 10-Q filed
30 Nov 202013.73%35.28
15 Dec 202013.69%36.34
31 Dec 202013.49%23.29

See also: Nektar Therapeutics's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.